ArticleNucleic acid therapeutics2013
A computationally designed DNA aptamer template with specific binding to phosphatidylserine.
Article in Nucleic acid therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Evaluation of Artificial Intelligence-Generated DNA Aptamers Against Treponema pallidum Surface Proteins.Journal of fluorescence · 2026Article
- Preparation of genetically or chemically engineered exosomes and their therapeutic effects in bone regeneration and anti-inflammation.Frontiers in bioengineering and biotechnology · 2024Review
- Aptamer engineering exosomes loaded on biomimetic periosteum to promote angiogenesis and bone regeneration by targeting injured nerves via JNK3 MAPK pathway.Materials today. Bio · 2022Article
- Structure- and Interaction-Based Design of Anti-SARS-CoV-2 Aptamers.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Article
- Cell Surface Binding and Lipid Interactions behind Chemotherapy-Drug-Induced Ion Pore Formation in Membranes.Membranes · 2021Article
- Methods and Applications of In Silico Aptamer Design and Modeling.International journal of molecular sciences · 2020Review
- Dataset on interactions of membrane active agents with lipid bilayers.Data in brief · 2020Article
- Aptamer Bioinformatics.International journal of molecular sciences · 2017Review
- Opportunities in the design and application of RNA for gene expression control.Nucleic acids research · 2016Review
- Phenomenology and energetics of diffusion across cell phase states.Saudi journal of biological sciences · 2015Article
- Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.Molecules (Basel, Switzerland) · 2015Review
- Mathematical and computational modeling in biology at multiple scales.Theoretical biology & medical modelling · 2014Review
- Aptamers as both drugs and drug-carriers.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phospholipid phosphatidylserine (PS) is an early marker exploited for detecting apoptosis (PS externalization in the cell membrane bilayer) and one factor that is associated with increased amyloid plaque deposition in transmissible spongiform encephalopathies (TSEs). PS can therefore be considered as a promising target for diagnosis or treatment of diseases. Aptamers (short nucleic acid sequences) are a particularly attractive class of materials among those currently considered for targeting PS. Here we applied an entropy based seed-and-grow strategy to design a DNA aptamer template to bind specifically to PS. The binding properties of designed aptamers were investigated computationally and experimentally. The studies identify the sequence, 5'-AAAGAC-3', as the preferred template for further modifications and studies toward its practical implementations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.